The first patient has been enrolled in a Phase 3 clinical trial of Tyvaso (treprostinil) inhalation solution for patients…
Lindsey Shapiro, PhD
Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lindsey Shapiro, PhD
NP-120 (ifenprodil), an investigational treatment for idiopathic pulmonary fibrosis (IPF) and chronic cough, continues to demonstrate an ability to…
Accord Healthcare has released a generic version of Esbriet (pirfenidone) for people in the U.S. with idiopathic…
Enrollment is now complete in ZEPHYRUS-1, a Phase 3 trial of pamrevlumab, an investigational treatment for idiopathic pulmonary…
Bridge Biotherapeutics has entered an exclusive in-licensing agreement with Shaperon to develop BBT-209, an investigational therapy for idiopathic…